Concordant to the western blotting, we observed significant reduction in γ-H2AX in the combination therapy compared with DOX mono-treatment, further supporting that OTS193320 plays a critical role in the regulation of γ-H2AX formation in breast cancer cells (Figure 3C, 3D). The gene discussed is H2AX; the disease is breast cancer.